Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J's abiraterone is cleared for use two months ahead of schedule. Pricing of $5,000 a month is much lower than Dendreon's Provenge, approved for earlier stage disease.
You may also be interested in...
Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter
Sanofi's Q3 sales grow by 10% and net income by 4.1% as Genzyme acquisition compensates for increasing generic competition to leading products.
Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter
Sanofi's Q3 sales grow by 10% and net income by 4.1% as Genzyme acquisition compensates for increasing generic competition to leading products.
Despite J&J’s Woes, Wall Street Sees Turnaround In Pharma Business
Johnson & Johnson’s pharma business appears to be weathering headwinds that are hobbling its consumer and medical device sales. Pharma accounted for 36% of JNJ’s 2010 sales of $61.6 billion.